Antiplatelet agents in cardiovascular disease

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 3, 2011, Pages 306-309

  Lopes, Renato D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aspirin; Clopidogrel; Coronary artery disease; Novel antiplatelet agents; Platelet aggregation inhibition

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ELINOGREL; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 INHIBITOR; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBIN; THROMBIN RECEPTOR ANTAGONIST; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; VAROPAXAR; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DOSE TIME EFFECT RELATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DYSPNEA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION;

ASPIRIN; CARDIOVASCULAR DISEASES; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE; TIME FACTORS; UNITED STATES;

EID: 79958117692     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0558-9     Document Type: Conference Paper

References (16)

1. Gharacholou SM, Alexander KP (2006) Issues with care in the elderly patient presenting with acute ischemia. Curr Heart Fail Rep 3:51-56 (Pubitemid 44623904)
2. Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Circulation 116:803-877
3. Antman EM, Hand M, Armstrong PW et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 117:296-329
4. Task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of European society of cardiology (2007) guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598-1660
5. Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology. Eur Heart J 29:2909-2945
6. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
7. Becker RC, Meade TW, Berger PB et al (2008) The primary and secondary prevention of coronary artery disease: American college of chest physicians evidence-based clinical practice guidelines (8th edn). Chest 133:776S-814S
8. Wallentin L (2009) P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30:1964-1977
9. Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502 (Pubitemid 32758501)
10. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015 (Pubitemid 350106708)
11. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057
12. TRA*CER Executive and Steering Committees (2009). The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA*CER) trial: study design and rationale. Am Heart J 158;327-334
13. Morrow DA, Scirica BM, Fox KA et al (2009) Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 158:335-341
14. Lopes RD, Elliott LE, White HD et al (2009) Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 30(16):2019-2028
15. Lopes RD, Starr A, Pieper CF et al (2010) Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med 123:134-140
16. Hansen ML, Sørensen R, Clausen MT et al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170:1433-1441